Nguyen
12-10-2023, 05:49 PM
All Relevant Subgroups With ESR1-Mutant MBC Derive PFS Benefit With Elacestrant
https://www.oncnursingnews.com/view/all-relevant-subgroups-with-esr1-mutant-mbc-derive-pfs-benefit-with-elacestrant
"...In patients with HER2-low expression, median PFS was 9.03 months vs 1.87 months, respectively (HR, 0.301; 95% CI, 0.142-0.604)..."
https://www.oncnursingnews.com/view/all-relevant-subgroups-with-esr1-mutant-mbc-derive-pfs-benefit-with-elacestrant
"...In patients with HER2-low expression, median PFS was 9.03 months vs 1.87 months, respectively (HR, 0.301; 95% CI, 0.142-0.604)..."